A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Planting AS, Sonneveld P, van der Gaast A, Sparreboom A, van der Burg ME, Luyten GP, de Leeuw K, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB Jr, Verweij J.
Planting AS, et al. Among authors: de leeuw k, de boer dennert m.
Cancer Chemother Pharmacol. 2005 Jan;55(1):91-9. doi: 10.1007/s00280-004-0854-6. Epub 2004 Jul 28.
Cancer Chemother Pharmacol. 2005.
PMID: 15565444
Clinical Trial.